Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology. Following a substantial strategic ...
31% reduction of greenhouse gas emissions 4% increase for electricity generated from renewable sources 5% reduction in total water consumption Representing changes from 2023 to 2024 WAYNE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback